Use of donepezil for neurocognitive recovery after brain injury in adult and pediatric populations:a scoping review  

作　　者：Avery L.Miller Nathan K.Evanson J.Michael Taylor 

机构地区：[1]University of Cincinnati College of Medicine,Cincinnati,OH,USA [2]Department of Pediatrics,University of Cincinnati,Cincinnati,OH,USA [3]Department of Neurology and Rehabilitation Medicine,University of Cincinnati,Cincinnati,OH,USA [4]Division of Pediatric Rehabilitation Medicine,Cincinnati Children’s Hospital Medical Center,Cincinnati,OH,USA [5]Division of Neurology,Cincinnati Children’s Hospital Medical Center,Cincinnati,OH,USA

出　　处：《Neural Regeneration Research》2024年第8期1686-1695,共10页中国神经再生研究（英文版）

基　　金：Division of Neurology,Cincinnati Children’s Hospital Medical Center(as a Medical Student Scholars Program award to ALM)。

摘　　要：There are few pharmacologic options for the treatment of cognitive deficits associated with traumatic brain injury in pediatric patients.Acetylcholinesterase inhibitors such as donepezil have been evaluated in adult patients after traumatic brain injury,but relatively less is known about the effect in pediatric populations.The goal of this review is to identify knowledge gaps in the efficacy and safety of acetylcholinesterase inhibito rs as a potential a djuvant treatment fo r neurocognitive decline in pediatric patients with traumatic brain injury.Investigators queried PubMed to identify literature published from database inception thro ugh June 2023 desc ribing the use of donepezil in young adult traumatic brain injury and pediatric patients with predefined conditions.Based on preselected search criteria,340 unique papers we re selected for title and abstra ct screening.Thirty-two reco rds were reviewed in full after eliminating preclinical studies and pape rs outside the scope of the project.In adult traumatic brain injury,we review results from 14 papers detailing 227 subjects where evidence suggests donepezil is well tole rated and shows both objective and patient-reported efficacy for reducing cognitive impairment.In children,3 pape rs report on 5 children recovering from traumatic brain injury,showing limited efficacy.An additional 15 pediatric studies conducted in populations at risk for cognitive dysfunction provide a broader look at safety and efficacy in 210 patients in the pediatric age group.Given its promise for efficacy in adults with traumatic brain injury and tole rability in pediatric patients,we believe further study of donepezil for children and adolescents with traumatic brain injury is warranted.

关 键 词：acetylcholinesterase inhibitor ADULT COGNITION DONEPEZIL PEDIATRICS traumatic brain injury 

分 类 号：R651.15[医药卫生—外科学]